EP1670817A4 - Utilisation d'une configuration spatiale pour moduler une fonction de proteine - Google Patents

Utilisation d'une configuration spatiale pour moduler une fonction de proteine

Info

Publication number
EP1670817A4
EP1670817A4 EP04782529A EP04782529A EP1670817A4 EP 1670817 A4 EP1670817 A4 EP 1670817A4 EP 04782529 A EP04782529 A EP 04782529A EP 04782529 A EP04782529 A EP 04782529A EP 1670817 A4 EP1670817 A4 EP 1670817A4
Authority
EP
European Patent Office
Prior art keywords
protein function
spatial configuration
modulate protein
modulate
spatial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP04782529A
Other languages
German (de)
English (en)
Other versions
EP1670817A2 (fr
Inventor
Guangwen Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HUIYANGTECH (USA) Inc
HUIYANGTECH USA Inc
Original Assignee
HUIYANGTECH (USA) Inc
HUIYANGTECH USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1670817(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by HUIYANGTECH (USA) Inc, HUIYANGTECH USA Inc filed Critical HUIYANGTECH (USA) Inc
Publication of EP1670817A2 publication Critical patent/EP1670817A2/fr
Publication of EP1670817A4 publication Critical patent/EP1670817A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
EP04782529A 2003-08-28 2004-08-26 Utilisation d'une configuration spatiale pour moduler une fonction de proteine Ceased EP1670817A4 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US49844903P 2003-08-28 2003-08-28
US49878503P 2003-08-28 2003-08-28
US49892303P 2003-08-28 2003-08-28
IN279MU2004 2004-03-05
IN280MU2004 2004-03-05
PCT/US2004/028068 WO2005021777A2 (fr) 2003-08-28 2004-08-26 Utilisation d'une configuration spatiale pour moduler une fonction de proteine

Publications (2)

Publication Number Publication Date
EP1670817A2 EP1670817A2 (fr) 2006-06-21
EP1670817A4 true EP1670817A4 (fr) 2008-07-16

Family

ID=34280101

Family Applications (3)

Application Number Title Priority Date Filing Date
EP10193126.9A Active EP2325202B1 (fr) 2003-08-28 2004-08-26 Utilisations d'interférons à structure spatiale modifiée
EP04782529A Ceased EP1670817A4 (fr) 2003-08-28 2004-08-26 Utilisation d'une configuration spatiale pour moduler une fonction de proteine
EP04809634.1A Active EP1663110B1 (fr) 2003-08-28 2004-08-26 Utilisations d'interferons a structure spatiale modifiee

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10193126.9A Active EP2325202B1 (fr) 2003-08-28 2004-08-26 Utilisations d'interférons à structure spatiale modifiée

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP04809634.1A Active EP1663110B1 (fr) 2003-08-28 2004-08-26 Utilisations d'interferons a structure spatiale modifiee

Country Status (8)

Country Link
EP (3) EP2325202B1 (fr)
JP (4) JP2007503812A (fr)
KR (2) KR20060130009A (fr)
AU (2) AU2004269390A1 (fr)
CA (2) CA2535902A1 (fr)
HK (2) HK1091756A1 (fr)
PL (2) PL1663110T3 (fr)
WO (2) WO2005034853A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
JP2007503812A (ja) * 2003-08-28 2007-03-01 ヒュイヤンテック（ユーエスエー），インク． 空間構造によるタンパク質の機能の調節
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
WO2006076014A2 (fr) * 2004-04-30 2006-07-20 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructions d'interferon-alpha destinees a etre utilisees dans le traitement du sras
US20080124302A1 (en) 2005-03-09 2008-05-29 Guangwen Wei Uses of Recombinant Super-Compound Interferons
CN102101886A (zh) * 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
TW201427681A (zh) * 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
CN111363726A (zh) 2018-12-26 2020-07-03 上海元宋生物技术有限公司 表达干扰素的溶瘤病毒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080958A1 (fr) * 2001-02-28 2002-10-17 Sichuan Biotechnology Research Center Interferon supercompose de recombinaison utilise comme inhibiteur de l'antigene de surface et de l'antigene e de l'hepatite b

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
EP0861321B1 (fr) * 1995-10-13 2006-05-31 President And Fellows Of Harvard College Phosphopantetheinyl transferases et leurs utilisations
US5874304A (en) * 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US20020043262A1 (en) * 2000-08-22 2002-04-18 Alan Langford Spray device
EP1355939A2 (fr) * 2000-11-03 2003-10-29 Pestka Biomedical Laboratories, Inc. Interferons, utilisations et compositions associees
JP2007503812A (ja) * 2003-08-28 2007-03-01 ヒュイヤンテック（ユーエスエー），インク． 空間構造によるタンパク質の機能の調節

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080958A1 (fr) * 2001-02-28 2002-10-17 Sichuan Biotechnology Research Center Interferon supercompose de recombinaison utilise comme inhibiteur de l'antigene de surface et de l'antigene e de l'hepatite b
EP1371373A1 (fr) * 2001-02-28 2003-12-17 Sichuan Biotechnology Research Center Interferon supercompose de recombinaison utilise comme inhibiteur de l'antigene de surface et de l'antigene e de l'hepatite b

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMATO I: "Silent no longer", CHEMICAL AND ENGINEERING NEWS, vol. 85, no. 4, 22 January 2007 (2007-01-22), pages 38 - 40 *
ANONYMOUS: "Infergen", 30 November 1998 (1998-11-30) *

Also Published As

Publication number Publication date
KR20060130009A (ko) 2006-12-18
CA2535982A1 (fr) 2005-04-21
EP1670817A2 (fr) 2006-06-21
JP5709800B2 (ja) 2015-04-30
JP2007503812A (ja) 2007-03-01
KR20060133949A (ko) 2006-12-27
EP2325202A1 (fr) 2011-05-25
AU2004279350A1 (en) 2005-04-21
AU2004279350B2 (en) 2011-03-10
PL2325202T3 (pl) 2015-03-31
WO2005021777A2 (fr) 2005-03-10
JP5663768B2 (ja) 2015-02-04
AU2004269390A1 (en) 2005-03-10
HK1091756A1 (en) 2007-01-26
EP1663110B1 (fr) 2013-12-18
WO2005034853A2 (fr) 2005-04-21
JP2011083292A (ja) 2011-04-28
PL1663110T3 (pl) 2014-07-31
EP2325202B1 (fr) 2014-10-22
EP1663110A4 (fr) 2008-07-16
WO2005021777A3 (fr) 2005-05-12
EP1663110A2 (fr) 2006-06-07
CA2535982C (fr) 2016-11-29
JP2007516214A (ja) 2007-06-21
JP2012162567A (ja) 2012-08-30
CA2535902A1 (fr) 2005-03-10
HK1158231A1 (en) 2012-09-14
WO2005034853A3 (fr) 2006-04-27

Similar Documents

Publication Publication Date Title
GB2408407B (en) Smart translation of generic configurations
ZA200600719B (en) Novel formulation of ropinirole
GB0202633D0 (en) Stabilization of protein preparations
EP1607081A4 (fr) Preparation cosmetique
HK1092703A1 (en) Stabilized formulations of phosphatidylserine
HK1080376A1 (en) Cosmetic preparation
EP1632213A4 (fr) Preparation cosmetique
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
EP1684790A4 (fr) Preparations homogenes de proteines chimeres
AU2003252072A8 (en) Modulation of protein kinase c-iota expression
HK1090065A1 (en) Preparation of somatostatin peptides
AU2003279841A1 (en) Uses of human zven antagonists
EP1670817A4 (fr) Utilisation d'une configuration spatiale pour moduler une fonction de proteine
HK1080448A1 (zh) 前列腺酰胺的製備
AU2003282338A8 (en) Determination of protein function
GB0218332D0 (en) Preparation of type pneumocytes
EP1512745A4 (fr) Proteine pigmentaire
EP1682572A4 (fr) Expression de proteines
AU2003250819A1 (en) Use of compounds that stimulate cgmp
AU2003246614A8 (en) Novel use of lipopeptide preparations
AU2003286273A8 (en) Decorrelation of signals
PL371427A1 (en) New uses of substituted aminoalkanephosphonic acids
AU2003217174A8 (en) Novel variants of rankl protein
EP1534756A4 (fr) Expression de proteines hydrophobes
GB0327742D0 (en) Novel uses of known drugs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060324

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1091846

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20080617

17Q First examination report despatched

Effective date: 20081127

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20110628

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1091846

Country of ref document: HK